Methamphetamine induces thoracic aortic aneurysm/dissection through C/EBPβ.
Methamphetamine induces thoracic aortic aneurysm/dissection through C/EBPβ.
复制标题
DOI:
10.1016/j.bbadis.2022.166447
复制
发表时间:
2022-09-01
期刊:
影响因子:
--
通讯作者:
中科院分区:
文献类型:
--
作者:
Thoracic aortic aneurysm/dissection (TAAD) is a life-threatening disease with diverse clinical manifestations. Although the association between methamphetamine (METH) and TAAD is frequently observed, the causal relationship between METH abuse and aortic aneurysm/dissection has not been established. This study was designed to determine if METH causes aortic aneurysm/dissection and delineate the underlying mechanism. A new TAAD model was developed by exposing METH to SD rats pre-treated with lysyl oxidase inhibitor β-aminopropionitrile (BAPN). Combination of METH and BAPN caused thoracic aortic aneurysm/dissection in 60% of rats. BAPN+METH significantly increased the expression and activities of both matrix metalloproteinase (MMP) 2 and MMP9, consistent with the severe elastin breakage and dissection. Mechanistically, METH increased CCAAT-enhancer binding protein β (C/EBPβ) expression by enhancing mothers against decapentaplegic homolog 3 (Smad3) and extracellular regulated protein kinase (ERK1/2) signaling. METH also promoted C/EBPβ binding to MMP2 and MMP9 promoters. Blocking C/EBPβ significantly attenuated METH+BAPN-induced TAAD and MMP2/MMP9 expression. Moreover, BAPN+METH promoted aortic medial smooth muscle cell (SMC) apoptosis through C/EBPβ-mediated IGFBP5/p53/PUMA signaling pathways. More importantly, the expression of C/EBPβ, MMP2/MMP9, and apoptosis-promoting proteins was increased in the aorta of human patients with thoracic aortic dissection, suggesting that the mechanisms identified in animal study could be relevant to human disease. Our study demonstrated that METH exposure has a casual effect on TAAD. C/EBPβ mediates METH-introduced TAAD formation by causing elastin breakage, medial cell loss and degeneration. Therefore, C/EBPβ may be a potential factor for TAAD clinical diagnosis or treatment.
登录
查看更多内容
DOI:
10.1126/science.1192149
发表时间:
2011-04-15
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Holm TM;Habashi JP;Doyle JJ;Bedja D;Chen Y;van Erp C;Lindsay ME;Kim D;Schoenhoff F;Cohn RD;Loeys BL;Thomas CJ;Patnaik S;Marugan JJ;Judge DP;Dietz HC
通讯作者:
Dietz HC
影响因子:
37.8
作者:
Bonderman, D;Gharehbaghi-Schnell, E;Lang, IM
通讯作者:
Lang, IM
DOI:
10.1042/cs20170252
发表时间:
2017-06-01
期刊:
Clinical science (London, England : 1979)
影响因子:
--
作者:
Jia LX;Zhang WM;Li TT;Liu Y;Piao CM;Ma YC;Lu Y;Wang Y;Liu TT;Qi YF;Du J
通讯作者:
Du J
影响因子:
4.8
作者:
Du SH;Qiao DF;Chen CX;Chen S;Liu C;Lin Z;Wang H;Xie WB
通讯作者:
Xie WB
影响因子:
20.1
作者:
Liu, Renjing;Lo, Lisa;Gamble, Jennifer R.
通讯作者:
Gamble, Jennifer R.